News | July 24, 2009

IABPs Aid Survival Rates in Patients With AMI Cardiogenic Shock

July 24, 2009 – The 30-day survival improved in patients with acute myocardial infarction complicated by cardiogenic shock who were treated with intra-aortic balloon pump (IABP) counterpulsation, according to a new study in the American Journal of Cardiology (vol. 104, issue 3, pages 327-332, August 2009).

Although IABPs are increasingly being used for the treatment of patients with cardiogenic shock from acute myocardial infarction, there is little data on the long-term outcomes. Researchers at the Thoraxcenter, Erasmus Medical Center in Rotterdam, The Netherlands, and the Department of Intensive Care Medicine, Academic Medical Center, Amsterdam, The Netherlands, evaluated the 30-day and long-term mortality and to identify predictors for 30-day and long-term all-cause mortality of patients with AMI complicated by cardiogenic shock who were treated with an IABP.

From January 1990 to June 2004, 300 consecutive patients treated with IABP were included. The mean age of the study population was 61 ± 11 years, and 79 percent of the patients were men. The survival rate until IABP removal after successful hemodynamic stabilization was 70 percent (n = 211). The overall cumulative 30-day survival rate was 58 percent. The 30-day mortality rate decreased over time from 52 percent in 1990 to 1994 to 36 percent in 2000 to 2004. Follow-up ranged from zero to 15 years. In patients who survived until IABP removal, the cumulative 1-, 5-, and 10-year survival rate was 69, 58 and 36 percent, respectively. The adjusted predictors of long-term mortality were arrhythmias during the intensive cardiac care unit stay (hazard ratio [HR] 1.8, 95 percent confidence interval [CI] 1.2 to 2.9) and renal failure during the intensive cardiac care unit stay (HR 2.5, 95 percent CI 1.3 to 5.1). After adjustment, treatment with primary percutaneous coronary intervention (HR 0.5, 95 percent CI 0.3 to 0.9) and coronary artery bypass grafting (HR 0.4, 95 percent CI 0.2 to 0.8) were associated with lower long-term mortality.

For more information:

Related Content

IABP recall for Maquet, Datascope intra-aortic balloon pump CS100 and CS300

The Datascope CS300 IABP console.

News | Hemodynamic Support Devices| June 20, 2017
June 20, 2017 — The U.S.
Technology | Intra-Aortic Balloon Pumps (IABP)| May 02, 2017
May 2, 2017 — The U.S. Food and Drug Administration (FDA) granted 510(k) clearance for the Teleflex Inc.
Impella CP heart pump, TCT 2016, intra-aortic balloon counterpulsation, IABP, clinical study
News | Intra-Aortic Balloon Pumps (IABP)| January 03, 2017 | Dave Fornell
The Impella CP heart pump (Abiomed) demonstrated no improvement in mortality for patients with myocardial infarction...
Teleflex, Arrow IAB catheter, intra-aortic balloon pump, worldwide recall
News | Intra-Aortic Balloon Pumps (IABP)| March 11, 2016
Teleflex Inc. announced the worldwide recall of Arrow International intra-aortic balloon catheter kits and percutaneous...
Sponsored Content | Webinar | Intra-Aortic Balloon Pumps (IABP)| December 22, 2015
The webinar "Hemodynamics of Counterpulsation" explained how the intra-aortic balloon pump (IABP) can increase diasto
IABP, peer review, Maquet, Journal of Invasive Cardiology
Feature | June 01, 2015
Maquet Getinge Group announced the publication of a manuscript describing the exploration of the hemodynamic effects of...
intraaortic balloon pumps, IABP, ventricular assist devices, VAD, cost effective
News | April 09, 2015
Maquet Cardiovascular USA announced publication of a manuscript comparing the clinical and economic impact of...
IABP, Datascope, Maquet, FDA recall
Feature | May 12, 2014
Datascope Corp./Maquet initiated a voluntary worldwide field correction of some of its intra-aortic balloon pumps (...
PVAD, percutaneous VAD, hemodynamic support, aortix

Procyrion Aortix is a catheter-deployed pVAD intended for long-term use in the treatment of chronic heart failure.

Feature | March 18, 2014 | Dave Fornell
Percutaneous ventricular assist (pVAD) devices offer more hemodynamic support than the 40-year-old gold standard of ...
News | October 01, 2013
Sunshine Heart Inc. has launched a website dedicated to providing information to patients suffering from moderate to...
Overlay Init